These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11478998)

  • 21. [Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].
    Gabay C
    Rev Med Suisse Romande; 2000 Jun; 120(6):529-33. PubMed ID: 11014098
    [No Abstract]   [Full Text] [Related]  

  • 22. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bringing the clinical experience with anakinra to the patient.
    Cohen SB; Rubbert A
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anakinra treatment of patients with rheumatoid arthritis.
    Calabrese LH
    Ann Pharmacother; 2002; 36(7-8):1204-9. PubMed ID: 12086555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 26. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2003; 32(5):376-83. PubMed ID: 14526457
    [No Abstract]   [Full Text] [Related]  

  • 28. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.
    den Broeder AA; de Jong E; Franssen MJ; Jeurissen ME; Flendrie M; van den Hoogen FH
    Ann Rheum Dis; 2006 Jun; 65(6):760-2. PubMed ID: 16269431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 34. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
    Schiff MH
    Drugs; 2004; 64(22):2493-501. PubMed ID: 15516150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study.
    Omdal R; Gunnarsson R
    Rheumatol Int; 2005 Aug; 25(6):481-4. PubMed ID: 15071755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB; Strand V; Aguilar D; Ofman JJ
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.
    Bresnihan B
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S32-4. PubMed ID: 14989427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW; White AJ
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2002 Jan; 287(1):33. PubMed ID: 11754690
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.